SCLX
NASDAQ · Pharmaceuticals
Scilex Holding Co
$5.16
+0.12 (+2.38%)
Financial Highlights (FY 2026)
Revenue
18.60M
Net Income
-220,512,151
Gross Margin
65.0%
Profit Margin
-1,185.8%
Rev Growth
-7.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 65.0% | 65.0% | 31.1% | 31.1% |
| Operating Margin | -1,168.0% | -1,051.2% | 21.5% | 26.8% |
| Profit Margin | -1,185.8% | -1,126.5% | 17.8% | 16.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 18.60M | 20.07M | 16.86M | 18.16M |
| Gross Profit | 12.08M | 13.04M | 5.24M | 5.64M |
| Operating Income | -217,207,671 | -210,972,268 | 3.63M | 4.87M |
| Net Income | -220,512,151 | -214,181,886 | 3.00M | 3.07M |
| Gross Margin | 65.0% | 65.0% | 31.1% | 31.1% |
| Operating Margin | -1,168.0% | -1,051.2% | 21.5% | 26.8% |
| Profit Margin | -1,185.8% | -1,126.5% | 17.8% | 16.9% |
| Rev Growth | -7.3% | -7.3% | +5.1% | -1.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 11.67M | 10.30M |
| Total Equity | — | — | 39.45M | 37.80M |
| D/E Ratio | — | — | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -214,525,196 | -219,942,732 | 6.50M | 7.12M |
| Free Cash Flow | — | — | 2.15M | 2.89M |